Literature DB >> 6638958

A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases.

B Hagberg, J Aicardi, K Dias, O Ramos.   

Abstract

Thirty-five patients, exclusively girls, from three countries had a uniform and striking progressive encephalopathy. After normal general and psychomotor development up to the age of 7 to 18 months, developmental stagnation occurred, followed by rapid deterioration of higher brain functions. Within one-and-a-half years this deterioration led to severe dementia, autism, loss of purposeful use of the hands, jerky truncal ataxia, and acquired microcephaly. The destructive stage was followed by apparent stability lasting through decades. Additional insidious neurological abnormalities supervened, mainly spastic parapareses, vasomotor disturbances of the lower limbs, and epilepsy. Prior extensive laboratory investigations have not revealed the cause. The condition is similar to a virtually overlooked syndrome described by Rett in the German literature. The exclusive involvement of females, correlated with findings in family data analyses, suggests a dominant mutation on one X chromosome that results in affected girls and nonviable male hemizygous conceptuses.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6638958     DOI: 10.1002/ana.410140412

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  339 in total

Review 1.  Rett syndrome and the MECP2 gene.

Authors:  T Webb; F Latif
Journal:  J Med Genet       Date:  2001-04       Impact factor: 6.318

Review 2.  Chromatin modification and disease.

Authors:  C A Johnson
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

3.  Rapid genotyping of common MeCP2 mutations with an electronic DNA microchip using serial differential hybridization.

Authors:  William A Thistlethwaite; Linda M Moses; Kristen C Hoffbuhr; Joseph M Devaney; Eric P Hoffman
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

Review 4.  Child and adolescent psychiatry: past scientific achievements and challenges for the future.

Authors:  Michael Rutter
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-05-11       Impact factor: 4.785

5.  Selective impact of MeCP2 and associated histone deacetylases on the dynamics of evoked excitatory neurotransmission.

Authors:  Erika D Nelson; Manjot Bal; Ege T Kavalali; Lisa M Monteggia
Journal:  J Neurophysiol       Date:  2011-04-20       Impact factor: 2.714

Review 6.  Brain-derived neurotrophic factor and neuropsychiatric disorders.

Authors:  Anita E Autry; Lisa M Monteggia
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

7.  Clinical profile of five patients with Rett syndrome and literature review.

Authors:  Riaz Ahmed
Journal:  Oman Med J       Date:  2007-10

8.  Enhanced cell death in MeCP2 null cerebellar granule neurons exposed to excitotoxicity and hypoxia.

Authors:  J C Russell; M E Blue; M V Johnston; S Naidu; M A Hossain
Journal:  Neuroscience       Date:  2007-10-11       Impact factor: 3.590

9.  Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment.

Authors:  Miriam Kron; C James Howell; Ian T Adams; Michael Ransbottom; Diana Christian; Michael Ogier; David M Katz
Journal:  J Neurosci       Date:  2012-10-03       Impact factor: 6.167

10.  TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys.

Authors:  Hailiang Liu; Yongchang Chen; Yuyu Niu; Kunshan Zhang; Yu Kang; Weihong Ge; Xiaojing Liu; Enfeng Zhao; Chencheng Wang; Shaoyun Lin; Bo Jing; Chenyang Si; Quan Lin; Xiaoying Chen; Haijun Lin; Xiuqiong Pu; Yingying Wang; Binlian Qin; Fang Wang; Hong Wang; Wei Si; Jing Zhou; Tao Tan; Tianqing Li; Shaohui Ji; Zhigang Xue; Yuping Luo; Liming Cheng; Qi Zhou; Siguang Li; Yi Eve Sun; Weizhi Ji
Journal:  Cell Stem Cell       Date:  2014-02-13       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.